Special Session 9

Attenzione: apre in una nuova finestra.

9 Tuesday, September 4, 7:45 – 9:30 am
Tailored multi-disciplinary therapeutic approach to the GERD patient
Chairs: D. Armstrong (Hamilton) – B. Gayet (Paris)
Discussant: P.O. Katz (Philadelphia)

  • Is SAP of greater value than SI in assessment of symptom reflux association? J.E. Richter (Tampa)
  • What is the clinical relevance of nocturnal acid reflux? V. Savarino (Genoa)
  • Which patients with GERD should have endoscopy? M. Hongo (Sendai)
    – Is there any value for endoscopy in NERD?
  • Inlet patch: is there any indication for biopsies?  for treatment? T. Ponchon (Lyons)
  • Is there a role for esophageal  manometry in the clinical management of GERD? D. Armstrong (Hamilton)
  • Should GERD patients be evaluated, before starting PPI therapy, with respect to their risks for respiratory tract infections, gastrointestinal infections, vitamin B12 deficiency and bone health? D. Armstrong (Hamilton)
  • How should response to a PPI be determined in clinical practice? S. Nasseri-Moghaddam (Tehran)
    – How long PPIs can be used safely?
  • Should ‘step down’ therapy be offered to all GERD patients who have responded to PPI therapy? D. Armstrong (Hamilton)
  • What is the relationship between obesity and PPI resistance? E. Savarino (Genoa)
  • What drugs have proven, sustained and clinically relevant effect on performance of esophageal  peristalsis?               
  • Following PPI failure, is ARS likely to be successful in GERD patients? B. Gayet (Paris)
  • How do existing and yet-to-be-developed techniques compare with standard medical or surgical therapy? L.L. Swanström (Portland) 
  • What is the role of pH-impedance in the choice of treatment other than PPI? R. Tutuian (Bern)                                               
  • Do prokinetic agents enhance esophageal contraction amplitude, velocity or peristalsis? P.O. Katz (Philadelphia)
  • What is appropriate patient selection for endoluminal antireflux procedures? R.I. Rothstein (Lebanon)